Literature DB >> 3177401

Renal excretion of hypoxanthine and xanthine in primary gout.

J G Puig1, F A Mateos, M L Jiménez, T H Ramos.   

Abstract

PURPOSE: The renal excretion of uric acid is usually diminished in primary gout with respect to increased serum urate levels. To determine whether the renal excretion of uric acid precursors, hypoxanthine and xanthine, is also abnormal in primary gout, the concentrations of these purines were measured in plasma and 24-hour urine samples in normal subjects, in patients with primary gout and uric acid underexcretion, and in patients with enzyme deficiencies that are known to result in over-production of uric acid. SUBJECTS AND METHODS: Three groups of subjects were studied: Group I consisted of 10 ambulatory healthy normal men; Group II consisted of 15 patients in whom primary gout was diagnosed; and Group III consisted of 10 patients with various enzyme defects known to produce an excessive synthesis of uric acid. In each subject, plasma and 24-hour urinary uric acid, hypoxanthine, xanthine, and creatinine concentrations were measured and the mean of three consecutive determinations was used. The fractional excretion of purine compounds was calculated from a formula. Hypoxanthine phosphoribosyltransferase, adenine phosphoribosyltransferase, and hemoglobin were also measured in each subject.
RESULTS: Plasma hypoxanthine and xanthine were increased in the two groups of patients compared with the control subjects. Urinary hypoxanthine and xanthine levels were reduced in gouty patients compared with control subjects, whereas levels were increased in patients with uric acid overproduction. A positive correlation was found between the renal clearances of uric acid, hypoxanthine, and xanthine.
CONCLUSION: The results indicate that the renal excretion of hypoxanthine and xanthine is severely impaired in most patients with primary gout.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3177401     DOI: 10.1016/s0002-9343(88)80091-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Serum uric Acid in smokers.

Authors:  Bassam E Hanna; Jamal M Hamed; Luma M Touhala
Journal:  Oman Med J       Date:  2008-10

Review 2.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; E Pascual; T Bardin; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

3.  Effect of cigarette smoking on plasma uric acid concentrations.

Authors:  Dhouha Haj Mouhamed; Asma Ezzaher; Fadoua Neffati; Wahiba Douki; Lotfi Gaha; Mohamed Fadhel Najjar
Journal:  Environ Health Prev Med       Date:  2010-12-18       Impact factor: 3.674

Review 4.  Clinical and biochemical aspects of uric acid overproduction.

Authors:  J García Puig; F A Mateos
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

6.  Renal excretion of urate by hyperuricaemic-hyperlipidemic patients.

Authors:  E Collantes Estevéz; F J Tinahones Madueño; A González Ruiz; J Añón Barbudo; M Pineda Priego; P Sánchez Guijo
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

7.  Hypoxanthine induces cholesterol accumulation and incites atherosclerosis in apolipoprotein E-deficient mice and cells.

Authors:  Hye-Myung Ryu; You-Jin Kim; Eun-Joo Oh; Se-Hyun Oh; Ji-Young Choi; Jang-Hee Cho; Chan-Duck Kim; Sun-Hee Park; Yong-Lim Kim
Journal:  J Cell Mol Med       Date:  2016-07-11       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.